Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial
Titel:
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial
Auteur:
Glass, Bertram Hasenkamp, Justin Wulf, Gerald Dreger, Peter Pfreundschuh, Michael Gramatzki, Martin Silling, Gerda Wilhelm, Christian Zeis, Matthias Görlitz, Anke Pfeiffer, Sebastian Hilgers, Reinhard Truemper, Lorenz Schmitz, Norbert